The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / CVS to Pay $5 Million to Resolve U.S. Drug Probe

CVS to Pay $5 Million to Resolve U.S. Drug Probe

July 12, 2017 • By Nate Raymond

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—CVS Health Corp. has paid $5 million to resolve allegations that pharmacies it operates in California failed to keep and maintain accurate records of prescription drugs, the U.S. Justice Department said on Tuesday.

You Might Also Like
  • Mallinckrodt Settles U.S. Opioid Drug Probe for $35 million
  • United Therapeutics to Pay $210 Million to Resolve U.S. Kickback Probe
  • CVS to Make Overdose Drug Naloxone Prescription-Free in Ohio

The deal follows an investigation that began in 2012 after the U.S. Drug Enforcement Administration noticed an increased number of thefts and unexplained losses of the opioid pain medication hydrocodone at some CVS stores, according to settlement papers.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The settlement came as U.S. authorities continue to grapple with a national opioid addiction epidemic, which has brought increased attention on companies involved in the distribution and production of prescription painkillers.

“The Department of Justice is committed to fighting prescription drug abuse, including the alarming rise of prescription opioid abuse that is plaguing the country,” U.S. Attorney Phillip Talbert in Sacramento said in a statement.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Opioids, including prescription painkillers and heroin, killed more than 33,000 people in the United States in 2015, more than any year on record, according to the U.S. Centers for Disease Control and Prevention.

According to Talbert’s office, from April 2011 through April 2013, CVS pharmacies failed to provide effective controls and procedures to guard against the diversion of controlled substances.

In addition to paying $5 million, CVS also entered into an administrative compliance plan with the DEA that covers 168 pharmacies in California, Talbert’s office said.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

As part of the settlement agreement, CVS acknowledged that during that time frame, some of its California pharmacies failed to fulfill certain record-keeping obligations under federal law.

But CVS contends any record-keeping failure did not cause drugs to be diverted for illegal uses, the settlement agreement said.

“As the settlement agreements recognize, CVS already maintains extensive programs and measures concerning compliance with the Controlled Substances Act and corresponding regulations,” CVS said in a statement.

Filed Under: Legal, Pharma Co. News Tagged With: CVS Health Corp, CVS pharmacies, hydrocodone, opioid, opioid crisis, opioid drug probe, pharmacy

You Might Also Like:
  • Mallinckrodt Settles U.S. Opioid Drug Probe for $35 million
  • United Therapeutics to Pay $210 Million to Resolve U.S. Kickback Probe
  • CVS to Make Overdose Drug Naloxone Prescription-Free in Ohio
  • Insys to Pay $150 Million to Settle U.S. Opioid Kickback Probe

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.